<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03365895</url>
  </required_header>
  <id_info>
    <org_study_id>1707634514</org_study_id>
    <secondary_id>NCI-2017-01413</secondary_id>
    <secondary_id>CIPN</secondary_id>
    <secondary_id>1707634514</secondary_id>
    <secondary_id>P30CA023074</secondary_id>
    <nct_id>NCT03365895</nct_id>
  </id_info>
  <brief_title>Diffusion Tensor Imaging in Predicting Development of Chemotherapy Induced Peripheral Neuropathy in Patients With Breast Cancer (CIPN)</brief_title>
  <acronym>CIPN</acronym>
  <official_title>Evaluating the Role of Diffusion Tensor Imaging in Predicting Development of Chemotherapy Induced Peripheral Neuropathy in Patients With Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Arizona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Arizona</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot early phase I trial studies how well diffusion tensor imaging works in predicting&#xD;
      development of chemotherapy induced peripheral neuropathy in patients with breast cancer.&#xD;
      Diffusion tensor imaging may help to get better pictures of the nerves of feet and lower legs&#xD;
      before and after chemotherapy treatment and may help to predict the risk of developing&#xD;
      peripheral neuropathy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To assess the changes in the fractional anisotropy (FA) and apparent diffusion coefficient&#xD;
      (ADC) values of the lower extremity nerves by diffusion tensor imaging (DTI) before&#xD;
      initiation and after completion of taxane chemotherapy in patients with breast cancer.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Establish normal and abnormal FA and ADC values of the lower extremity nerves.&#xD;
&#xD;
      II. Evaluate relationship of DTI findings of chemotherapy induced peripheral neuropathy&#xD;
      (CIPN) with self-reported Patient Neurotoxicity Questionnaire (PNQ) and Functional Assessment&#xD;
      of Cancer Therapy/Gynecologic Oncology Group-neurotoxicity questionnaire (FACT-GOT-NTX)&#xD;
      questionnaires.&#xD;
&#xD;
      III. Assess inter-reader variability in measuring FA and ADC values.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients undergo non-enhanced magnetic resonance imaging (MRI) of both lower extremities&#xD;
      using magnetic resonance neurography (MRN) and DTI prior to initiation and after completion&#xD;
      of standard of care chemotherapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 11, 2017</start_date>
  <completion_date type="Actual">October 2, 2020</completion_date>
  <primary_completion_date type="Actual">September 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in quantitative fractional anisotropy (FA) of the lower extremity nerves by diffusion tensor imaging (DTI)</measure>
    <time_frame>Pre-Treatment (0-30 days prior to receiving first chemotherapy) and Post-Treatment (0-30 days after last day of chemotherapy)</time_frame>
    <description>The quantitative DTI parameters measured before the initiation of and after completion of chemotherapy will be compared and used to calculate the degree of change. Descriptive statistics (with confidence interval [CI]) will be used for the current sample size.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in apparent diffusion coefficient (ADC) of the lower extremity nerves by diffusion tensor imaging (DTI)</measure>
    <time_frame>Pre-Treatment (0-30 days prior to receiving first chemotherapy) and Post-Treatment (0-30 days after last day of chemotherapy)</time_frame>
    <description>The quantitative DTI parameters measured before the initiation of and after completion of chemotherapy will be compared and used to calculate the degree of change. Descriptive statistics (with confidence interval [CI]) will be used for the current sample size.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inter-reader variability and reproducibility in measuring fractional anisotropy (FA) by diffusion tensor imaging (DTI)</measure>
    <time_frame>Pre-Treatment (0-30 days prior to receiving first chemotherapy) and Post-Treatment (0-30 days after last day of chemotherapy)</time_frame>
    <description>Inter-reader agreement in measuring the quantitative DTI measurements will be assessed by percentage agreement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inter-reader variability and reproducibility in measuring apparent diffusion coefficient (ADC) by diffusion tensor imaging (DTI)</measure>
    <time_frame>Pre-Treatment (0-30 days prior to receiving first chemotherapy) and Post-Treatment (0-30 days after last day of chemotherapy)</time_frame>
    <description>Inter-reader agreement in measuring the quantitative DTI measurements will be assessed by percentage agreement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Normal fractional anisotropy (FA) values of lower extremity nerves</measure>
    <time_frame>Pre-Treatment (0-30 days prior to receiving first chemotherapy) and Post-Treatment (0-30 days after last day of chemotherapy)</time_frame>
    <description>The normal FA and ADC values of the lower extremity nerves will be estimated using mean FA and ADC values with 95% CIs for before and after chemotherapy will be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Normal apparent diffusion coefficient (ADC) values of lower extremity nerves</measure>
    <time_frame>Pre-Treatment (0-30 days prior to receiving first chemotherapy) and Post-Treatment (0-30 days after last day of chemotherapy)</time_frame>
    <description>The normal FA and ADC values of the lower extremity nerves will be estimated using mean FA and ADC values with 95% CIs for before and after chemotherapy will be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral neuropathy severity questionnaires</measure>
    <time_frame>Pre-Treatment (0-30 days prior to receiving first chemotherapy) and on last day of chemotherapy</time_frame>
    <description>The correlation between FA and ADC values with the self-reported Patient Neurotoxicity Questionnaire and Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-neurotoxicity questionnaire will be evaluated using Pearson or spearman correlation coefficient.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Breast Carcinoma</condition>
  <condition>Breast Cancer</condition>
  <condition>Neuropathy;Peripheral</condition>
  <condition>Neuropathy</condition>
  <arm_group>
    <arm_group_label>Diagnostic (non-enhanced MRI using MRN and DTI)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo non-enhanced MRI of both lower extremities using MRN and DTI prior to initiation and after completion of standard of care chemotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Diffusion Tensor Imaging</intervention_name>
    <description>Undergo non-enhanced MRI using MRN and DTI</description>
    <arm_group_label>Diagnostic (non-enhanced MRI using MRN and DTI)</arm_group_label>
    <other_name>DIFFUSION TENSOR MRI</other_name>
    <other_name>DT-MRI</other_name>
    <other_name>DTI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Diagnostic (non-enhanced MRI using MRN and DTI)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Magnetic Resonance Imaging</intervention_name>
    <description>Undergo non-enhanced MRI using MRN and DTI</description>
    <arm_group_label>Diagnostic (non-enhanced MRI using MRN and DTI)</arm_group_label>
    <other_name>Magnetic Resonance Imaging Scan</other_name>
    <other_name>Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance</other_name>
    <other_name>MRI</other_name>
    <other_name>MRI Scan</other_name>
    <other_name>NMR Imaging</other_name>
    <other_name>NMRI</other_name>
    <other_name>Nuclear Magnetic Resonance Imaging</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Diagnostic (non-enhanced MRI using MRN and DTI)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Be capable of understanding the investigational nature of the study and all pertinent&#xD;
             aspects of the study&#xD;
&#xD;
          -  Be capable of signing and providing written consent in accordance with institutional&#xD;
             and federal guidelines&#xD;
&#xD;
          -  Have a histologically-confirmed diagnosis of breast cancer&#xD;
&#xD;
          -  Need to be treated with taxane containing chemotherapy as determined by their treating&#xD;
             physician&#xD;
&#xD;
          -  Be able to undergo magnetic resonance (MR) imaging&#xD;
&#xD;
          -  Be willing and able to comply with scheduled visits, treatment plan, and MR imaging&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have non-MRI compatible metallic objects on/in body&#xD;
&#xD;
          -  Have metallic hardware in the lower extremity which is MR compatible however would&#xD;
             create too much artifact for MR examination&#xD;
&#xD;
          -  Are unable to lay still in the MR scanner for length of examination&#xD;
&#xD;
          -  Have severe claustrophobia&#xD;
&#xD;
          -  Have pre-existing peripheral neuropathy from other medical conditions or due to cancer&#xD;
&#xD;
          -  Have diagnosis of diabetes&#xD;
&#xD;
          -  Pregnant patients&#xD;
&#xD;
          -  Prior exposure to neurotoxic chemotherapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pavani Chalasani, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Arizona Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lana Gimber, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Arizona Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The University of Arizona Cancer Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 16, 2017</study_first_submitted>
  <study_first_submitted_qc>December 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 7, 2017</study_first_posted>
  <last_update_submitted>November 18, 2020</last_update_submitted>
  <last_update_submitted_qc>November 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>diffusion</keyword>
  <keyword>tensor</keyword>
  <keyword>imaging</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>peripheral neuropathy</keyword>
  <keyword>breast cancer</keyword>
  <keyword>MRI</keyword>
  <keyword>Magnetic Resonance Imaging</keyword>
  <keyword>Diffusion Tensor Imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

